Your session is about to expire
← Back to Search
[18F]Florbetapir for Alzheimer's Disease
Phase 1
Waitlist Available
Led By David Russell
Research Sponsored by Invicro
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
Study Summary
The overall goal of this protocol is to compare amyloid burden assessed by amyloid PET to plasma P-tau217 levels.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Creation of a database of brain amyloid deposition by region using PET signal-to-noise ratio, SUVr .
Secondary outcome measures
Creation of a database of blood P-tau217 and other blood biomarkers.
Trial Design
1Treatment groups
Experimental Treatment
Group I: [18F]FlorbetapirExperimental Treatment1 Intervention
Participants will undergo amyloid PET imaging with an approved amyloid radiotracer (ie, [18F]Florbetapir (Amyvid™)) to assess β-amyloid neuritic plaque density.
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
InvicroLead Sponsor
16 Previous Clinical Trials
185 Total Patients Enrolled
David RussellPrincipal InvestigatorInvicro
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger